Bavarian Nordic, the vaccine maker, on July 28 said that it has agreed in principle for roughly $3 bn take-private offer from private equity firms Permira and Nordic Capital.
Apparently, the board of directors of the company plan to unanimously recommend the deal to the shareholders of Bavarian Nordic when they go on to formally receive Nordic capital as well as Permira’s bid in the weeks to come.
Under the deal, both the firms are going to pay 233 Danish kroner for every Bavarian Nordic share, thereby representing a 21% premium to the closing price of the company on July 30, which is one day before the vaccine maker went on to confirm that it was having takeover talks.
According to Luc Debruyne, the CEO of Bavarian Nordic, the $3 bn take-private offer has been received from Nordic Capital as well as Permira happens to be the result of intense negotiations that were aimed at securing the best possible terms for Bavarian Nordic shareholders. Together along with Permira as well as Nordic Capital, the growth strategy of Bavarian Nordic can indeed get the speed it desires.
It is well to be noted that the companies anticipate completing their deal in the fourth quarter of 2025.
Apparently, Bavarian Nordic has developed vaccines pertaining to mpox as well as smallpox, the former of which had thrust the company into the global spotlight a few years back during the most recent outbreak of that disease. It also happens to have a shot against the chikungunya virus, which is named Vimkunya, that has been approved in the UK, the US, and also the EU.
The company launched Vimkunya in the US in March 2025 and has secured a recommendation coming from the Centers for Disease Control and Prevention in May 2025. It anticipates launching the shot across the UK as well as the EU in 2025 itself.
Interestingly, Bavarian Nordic has indeed hit certain setbacks in the past, having scrapped a vaccine pertaining to respiratory syncytial virus in 2023 after a late-stage trial result turned out to be negative.
However, its revenue is now witnessing the surge in rising demand when it comes to its travel vaccines as well as continued support for its contract business related to government. Interestingly, the US government recently exercised its options for additional supply of the smallpox vaccine from Bavarian Nordic, which is going to increase revenue in 2025 and also secure business for 2026.
According to Nordic Capital and Permira, they plan to continue with their desire to operate Bavarian Nordic in the same way as it is done presently, which includes even the main facilities of the company.
It is well to be noted that Nordic Capital and Permira will be required to secure more than 90% of the voting rights as well as share capital of Bavarian Nordic in order to complete this deal.
